Protagenic Therapeutics, Inc.\new (PTIX) Return on equity 2016–2023
Protagenic Therapeutics, Inc.\new (PTIX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-136.3%FY2023 · since FY2016: -91.9% → -136.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -136.3% | -84.9 pp |
| FY2022 | -51.4% | -5.9 pp |
| FY2021 | -45.5% | — |
| FY2016 | -91.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice